BioVie

63 articles about BioVie

• BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress

  5/16/2023

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison’s Disease was presented at the 2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD), held in Chicago, IL May 13-16, 2023.

• BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting

  4/20/2023

  BioVie Inc. today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry Annual Meeting.

• BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

  4/17/2023

  BioVie Inc.  today announced data abstracts from its Phase 2 trials evaluating NE7107 in degenerative dementias and Parkinson’s Disease will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, to be held virtually and in Boston, MA, April 22-27, 2023.

• BioVie Announces Registration Details for "BioVie Day" Webinar Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time

  3/14/2023

  BioVie Inc. today announced registration details for BioVie Day— a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time. 

• BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference

  3/9/2023

  BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced the participation of its management team in the Oppenheimer 33rd Annual Healthcare Conference, to be held virtually March 13-15, 2023.

• BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo

  3/6/2023

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced additional preliminary findings from its Parkinson’s Disease Phase 2 trial.

• BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

  3/2/2023

  BioVie Inc. today announced that its NM101 trial evaluating NE3107 in the treatment of patients with Alzheimer’s Disease, has achieved its revised enrollment target of 400 patients.

• BioVie Announces “BioVie Day” to be held March 23, 2023

  2/21/2023

  BioVie Inc.  today announced that BioVie Day will be held March 23, 2023 at 10 a.m. Eastern Standard Time.

• BioVie Issues Letter to Shareholders

  12/7/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued a letter to shareholders.

• BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

  12/6/2022

  BioVie Inc.  today announced encouraging data suggesting that NE3107 has an impact on improving patients’ DNA methylation profiles, potentially impacting biomakers of aging-related disease states.

• BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

  12/5/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced positive results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease (PD) and Alzheimer’s Disease (AD).

• BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 PatientsCompany is Opting to Increase Study Size to 400 due to Fast Enrollment Pace

  11/29/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that more than 316 patients have enrolled in its Phase 3 trial, thereby achieving its trial enrollment target.

• BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting

  11/15/2022

  BioVie Inc., today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer’s Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD).

• BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

  10/24/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022.

• BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

  10/19/2022

  BioVie Inc. announced that the Company’s Phase 2 trial assessing NE3107’s potential pro-motoric impact in Parkinson’s disease has fully enrolled 44 patients.

• BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference

  9/29/2022

  BioVie Inc. announced the participation of its management team in a panel discussion and one-on-one investor meetings at Cantor Fitzgerald’s Neurology & Psychiatry Conference, to be held October 6-7, 2022, in San Francisco, CA.

• 

  Clinical Catch-Up: Good News for BioVie, Regeneron, Relay and More

  9/12/2022

  ​​​​​​​The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.
• 

  BioVie Biomarker Study Points to Improvements in Alzheimer's

  9/8/2022

  ​​​​​​​BioVie announced topline results from a Phase II biomarker study in Alzheimer's disease showing patient improvements in cognition and reductions in neural inflammation.

• BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

  9/7/2022

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced topline results from an investigator-Sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer’s Disease.

• BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

  6/23/2022

  BioVie Inc.   (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome (“HRS”) has been issued by the U.S. Patent &Trademark Office.